Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity
暂无分享,去创建一个
Adrian V. S. Hill | A. Hill | S. Gilbert | Alexandra J. Spencer | Sarah C. Gilbert | N. Alharbi | Naif Khalaf Alharbi
[1] James M. Wilson,et al. Single-Dose Protection against Plasmodium berghei by a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron A , 2008, Journal of Virology.
[2] T. Pollard,et al. Vaccinia virus expresses a novel profilin with a higher affinity for polyphosphoinositides than actin. , 1994, Biochemistry.
[3] I. Haga,et al. Vaccinia virus protein A46R targets multiple Toll-like–interleukin-1 receptor adaptors and contributes to virulence , 2005, The Journal of experimental medicine.
[4] D. Stuart,et al. Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein , 2007, The Journal of general virology.
[5] M. Brown,et al. Innate immune recognition of poxviral vaccine vectors , 2011, Expert review of vaccines.
[6] C. Sorzano,et al. Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways , 2013, PloS one.
[7] D. Tscharke,et al. The vaccinia virus B9R protein is a 6 kDa intracellular protein that is non-essential for virus replication and virulence. , 2002, The Journal of general virology.
[8] D. Tscharke,et al. The Vaccinia Virus Superoxide Dismutase-Like Protein (A45R) Is a Virion Component That Is Nonessential for Virus Replication , 2001, Journal of Virology.
[9] N. Letvin,et al. Kinetics of Recombinant Adenovirus Type 5, Vaccinia Virus, Modified Vaccinia Ankara Virus, and DNA Antigen Expression In Vivo and the Induction of Memory T-Lymphocyte Responses , 2008, Clinical and Vaccine Immunology.
[10] G. Pantaleo,et al. Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens , 2012, PloS one.
[11] H. Stickl,et al. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. , 1978, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe B: Hygiene, Betriebshygiene, praventive Medizin.
[12] G. Sutter,et al. Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling. , 2013, Vaccine.
[13] D. Tscharke,et al. A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence. , 2002, The Journal of general virology.
[14] J. Altman,et al. Deletion of Specific Immune-Modulatory Genes from Modified Vaccinia Virus Ankara-Based HIV Vaccines Engenders Improved Immunogenicity in Rhesus Macaques , 2012, Journal of Virology.
[15] C. Sorzano,et al. Deletion of the Vaccinia Virus N2L Gene Encoding an Inhibitor of IRF3 Improves the Immunogenicity of Modified Vaccinia Virus Ankara Expressing HIV-1 Antigens , 2014, Journal of Virology.
[16] M. Esteban,et al. Improving the MVA Vaccine Potential by Deleting the Viral Gene Coding for the IL-18 Binding Protein , 2012, PloS one.
[17] S. Lockhart,et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial , 2013, The Lancet.
[18] G. Smith,et al. A vaccinia serine protease inhibitor which prevents virus-induced cell fusion. , 1992, The Journal of general virology.
[19] C. Staib,et al. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. , 2003, Current drug targets. Infectious disorders.
[20] R. L. Roper,et al. Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching. , 2011, Vaccine.
[21] A. Hill,et al. Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass , 2010, Science Translational Medicine.
[22] Nancy A. Jenkins,et al. Simple and highly efficient BAC recombineering using galK selection , 2005, Nucleic acids research.
[23] C. Sorzano,et al. Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions , 2010, PloS one.
[24] G. Smith,et al. Vaccinia virus gene SalF5R is non-essential for virus replication in vitro and in vivo. , 1992, The Journal of general virology.
[25] C. Staib,et al. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. , 2000, BioTechniques.
[26] D. Webster,et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. , 2006, Vaccine.
[27] C. Sorzano,et al. A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses , 2011, PloS one.
[28] H. Schäfer,et al. MVA-Stufenimpfung gegen Pocken , 1974 .
[29] A. Bowie,et al. Vaccinia Virus Protein C6 Is a Virulence Factor that Binds TBK-1 Adaptor Proteins and Inhibits Activation of IRF3 and IRF7 , 2011, PLoS pathogens.
[30] F. Falkner,et al. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. , 1998, Virology.
[31] D. Spehner,et al. Detection of a protein encoded by the vaccinia virus C7L open reading frame and study of its effect on virus multiplication in different cell lines. , 1993, The Journal of general virology.
[32] H. Baker,et al. Roles of Vaccinia Virus Genes E3L and K3L and Host Genes PKR and RNase L during Intratracheal Infection of C57BL/6 Mice , 2010, Journal of Virology.
[33] B. Moss,et al. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. , 1997, Virology.
[34] A. Hill,et al. Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA) , 2008, PloS one.
[35] T. Peto,et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. , 2003, Vaccine.
[36] Margarida Saraiva,et al. A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[37] H. Stickl,et al. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism. , 1978 .
[38] P. Romero,et al. Isolation and characterization of protective cytolytic T cells in a rodent malaria model system. , 1990, Immunology letters.
[39] A. Mayr,et al. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. , 1974, Deutsche medizinische Wochenschrift.
[40] D. Tscharke,et al. Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. , 2006, The Journal of general virology.
[41] S. Hornemann,et al. Replication of Modified Vaccinia Virus Ankara in Primary Chicken Embryo Fibroblasts Requires Expression of the Interferon Resistance Gene E3L , 2003, Journal of Virology.
[42] Geoffrey L. Smith,et al. Steroid Hormone Synthesis by Vaccinia Virus Suppresses the Inflammatory Response to Infection , 2003, The Journal of experimental medicine.
[43] H. Ren,et al. Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence , 2013, The Journal of general virology.
[44] Geoffrey L. Smith,et al. Vaccinia Virus Interleukin-18-Binding Protein Promotes Virulence by Reducing Gamma Interferon Production and Natural Killer and T-Cell Activity , 2003, Journal of Virology.
[45] D. Tscharke,et al. A study of the vaccinia virus interferon-γ receptor and its contribution to virus virulence , 2002 .
[46] M. Esteban,et al. Cellular and Biochemical Differences between Two Attenuated Poxvirus Vaccine Candidates (MVA and NYVAC) and Role of the C7L Gene , 2006, Journal of Virology.
[47] B. Moss,et al. Vaccinia virus A43R gene encodes an orthopoxvirus-specific late non-virion type-1 membrane protein that is dispensable for replication but enhances intradermal lesion formation. , 2010, Virology.
[48] M. Esteban,et al. Clinical applications of attenuated MVA poxvirus strain , 2013, Expert review of vaccines.
[49] C. Staib,et al. Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. , 2005, The Journal of general virology.
[50] J. Ramírez,et al. Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a Vaccine , 2000, Journal of Virology.
[51] A. Banham,et al. Characterization of vaccinia virus gene B12R. , 1993, The Journal of general virology.
[52] J. Heeney,et al. Viruses as vaccine vectors for infectious diseases and cancer , 2010, Nature Reviews Microbiology.
[53] I. Siemion,et al. The immunosuppressive activity of peptide fragments of vaccinia virus C10L protein and a hypothesis on the role of this protein in the viral invasion , 2002, Peptides.
[54] B. Moss,et al. Cell proliferative response to vaccinia virus is mediated by VGF. , 1988, Virology.
[55] B. Moss,et al. Identification of the vaccinia virus gene encoding an 18-kilodalton subunit of RNA polymerase and demonstration of a 5' poly(A) leader on its early transcript , 1990, Journal of virology.